Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Brief summary (registry, in English)

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study treatment (either avacincaptad pegol or Sham).

What you commit to

• Study type: Interventional · Phase 3
• Participants enrolled: 278
• From 26 Sept 2022 to the primary completion date, 10 Apr 2025
• 117 sites in 17 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (117)

Sites in registry order. Pick your city on the disease page to sort them by distance.